MedTrace Logo

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

NCT05273827 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2024-01-05

No results posted yet for this study

Summary

To observe the effect of preoperative anti-PD-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative delirium.

Conditions

  • Immunotherapy
  • Analgesia
  • NSCLC
  • Delirium

Interventions

DRUG

neoadjuvant immunotherapy

Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.

DRUG

Neoadjuvant chemotherapy

Cis-platinum combined with paclitaxel or pemetrexed

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Tianjin Chest Hospital

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Kaiyuan Wang, MD · Tianjin Medical University Cancer Institute and Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-22
Primary Completion
2023-12-20
Completion
2024-01-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05273827 on ClinicalTrials.gov